Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many claims align directionally with Eliquis FDA labeling themes (thrombotic risk with premature discontinuation; neuraxial/spinal-epidural hematoma risk). However, the provided audit prompt includes only two relevant label topics and does not verify or cite the broader bleeding/interaction/NSAID-related statements, making several claims unsupported/unalignable to the supplied label excerpt.
Category Scores
Accurate Statements
PREMATURE DISCONTINUATION of ELIQUIS increases the risk of thrombotic events.
Supported by provided excerpt: 5.1 Increased Risk of Thrombotic Events after Premature Discontinuation (premature discontinuation of any oral anticoagulant including ELIQUIS, without adequate alternative anticoagulation increases thrombotic events risk).
SPINAL/EPIDURAL HEMATOMA can occur with neuraxial anesthesia or spinal/epidural puncture and can result in long-term or permanent paralysis.
Supported by provided excerpt: 5.3 Spinal/Epidural Anesthesia or Puncture (risk of epidural/spinal hematoma, can result in long-term or permanent paralysis; includes monitoring guidance).
If signs/symptoms of spinal/epidural hematoma occur, patients should seek emergent medical attention.
Supported by provided excerpt: 17 Patient Counseling Information for neuraxial intervention (advise patients to watch for signs/symptoms and seek emergent medical attention if they occur).
Unsupported Statements
Ibuprofen can increase bleeding risk when used with Eliquis (apixaban).
Not supported by the supplied Eliquis label excerpts provided in the prompt (only 5.1 and 5.3 are shown; no NSAID/ibuprofen interaction or general bleeding risk statements with NSAIDs are included in the provided text).
Eliquis directly inhibits clot formation.
The provided excerpts describe apixaban as an anticoagulant (factor Xa inhibitor) but do not support this specific mechanistic phrasing about 'directly inhibits clot formation.'
Ibuprofen, as an NSAID, can irritate the stomach.
Not addressed in the supplied Eliquis label excerpts.
Ibuprofen can increase bleeding tendencies.
Not supported by the supplied Eliquis label excerpts.
Many clinicians recommend avoiding NSAIDs like ibuprofen unless a prescriber says it’s appropriate.
Not supported by the supplied label excerpts (no clinician-recommendation language is included).
Acetaminophen (paracetamol) is often the preferred option for pain or fever when taking Eliquis.
Not supported by the supplied Eliquis label excerpts.
Acetaminophen does not act like an NSAID on platelets.
Not addressed in the supplied Eliquis label excerpts.
Acetaminophen generally has a lower bleeding risk than ibuprofen.
Not supported by the supplied Eliquis label excerpts.
Doses of acetaminophen should stay within the label and clinician guidance.
Not supported by the supplied Eliquis label excerpts.
Acetaminophen guidance should be followed closely in people with liver disease or heavy alcohol use.
Not supported by the supplied Eliquis label excerpts.
Using ibuprofen with Eliquis can raise the chance of bleeding.
Not supported by the supplied Eliquis label excerpts.
Using ibuprofen with Eliquis can increase the risk of gastrointestinal bleeding.
Not supported by the supplied Eliquis label excerpts.
The bleeding risk tends to be higher with higher ibuprofen doses.
Not supported by the supplied Eliquis label excerpts.
The bleeding risk tends to be higher with longer duration of ibuprofen use.
Not supported by the supplied Eliquis label excerpts.
The bleeding risk tends to be higher with older age.
Not supported by the supplied Eliquis label excerpts.
The bleeding risk tends to be higher if a person takes other blood thinners or antiplatelet drugs.
The provided excerpts do not include this specific generalization; only neuraxial/puncture risk with concomitant medicinal products affecting hemostasis is described.
A single dose of ibuprofen may not cause an immediate problem for many people taking Eliquis.
Not supported by the supplied Eliquis label excerpts.
After taking ibuprofen, people should avoid further NSAID doses.
Not supported by the supplied Eliquis label excerpts.
People should contact their prescriber or pharmacist for advice after taking ibuprofen.
Not supported by the supplied Eliquis label excerpts.
Seek urgent care if signs of bleeding occur, including black or tarry stools; vomiting blood or material that looks like coffee grounds; unusual bruising, prolonged bleeding, or blood in urine; severe/persistent headache, dizziness, weakness, or fainting.
The provided excerpts include neuraxial hematoma monitoring and emergent attention, but do not enumerate these specific bleeding signs.
A prescriber may consider ibuprofen if the benefits outweigh the risks.
Not supported by the supplied Eliquis label excerpts.
Ibuprofen may be considered when there are no strong bleeding risk factors.
Not supported by the supplied Eliquis label excerpts.
If ibuprofen is used, it may be used at the lowest effective dose for the shortest time.
Not supported by the supplied Eliquis label excerpts.
A clinician may recommend stomach protection in higher-risk patients taking Eliquis and considering ibuprofen.
Not supported by the supplied Eliquis label excerpts.
The decision to use ibuprofen with Eliquis is individualized based on factors including the reason for Eliquis use (e.g., atrial fibrillation vs. treatment of a clot).
Not supported by the supplied Eliquis label excerpts.
The decision to use ibuprofen with Eliquis is individualized based on factors including age, kidney function, bleeding history, and other medications.
Not supported by the supplied Eliquis label excerpts.
Other NSAIDs (e.g., naproxen, diclofenac) can increase bleeding risk when used with Eliquis.
Not supported by the supplied Eliquis label excerpts.
Aspirin or other antiplatelet drugs can increase bleeding risk when used with Eliquis.
Not supported by the supplied Eliquis label excerpts.
Taking other anticoagulants can increase bleeding risk when used with Eliquis.
Not supported by the supplied Eliquis label excerpts.
Some antidepressants (SSRIs/SNRIs) can increase bleeding risk when used with Eliquis.
Not supported by the supplied Eliquis label excerpts.
Certain antifungals or antibiotics that affect drug metabolism can interact with Eliquis and increase bleeding risk.
Not supported by the supplied Eliquis label excerpts.
Contradictions
Important Omissions
No explicit labeling guidance was provided for how ELIQUIS interacts with NSAIDs/ibuprofen (e.g., specific contraindications or warnings/precautions about concomitant NSAID use), because the prompt’s provided label excerpt does not include such sections and the evaluation cannot confirm these details.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Neuraxial hematoma and premature discontinuation themes are supported, but many other bleeding-risk and drug-interaction claims (especially NSAID/acetaminophen comparative risk and specific bleeding-sign lists) are not verifiable against the supplied label excerpts, which may lead to ungrounded guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most statements about ibuprofen/NSAIDs, acetaminophen preference, specific bleeding signs, and multiple drug classes are not supported by the provided Eliquis FDA label excerpts.
Suggested Improvement
Limit claims to the supplied on-label excerpted warnings/precautions (premature discontinuation thrombotic risk; spinal/epidural anesthesia/puncture hematoma risk with monitoring/emergent care) or provide the corresponding exact label sections for the NSAID/interactions and bleeding-sign counseling before asserting them.